secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001140361-24-026106
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin Therapeutics Q1 net loss $0.19/share; cash $23.6M; NAVIGATE trial on track for Q4 2024 interim data
--------------------------------------------------------------------------------

- Net loss $11.5M ($0.19 per share) for Q1 2024, unchanged from Q1 2023.
- Cash and equivalents $23.6M; additional $20M available from chairman's credit lines (two $10M facilities).
- Fifth DSMB recommended continuation of NAVIGATE Phase 2b/3 trial of belapectin in MASH cirrhosis without modifications.
- Interim top-line data from Phase 2b portion expected late Q4 2024.
- Appointed Khurram Jamil, M.D. as Vice President of Clinical Development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036124026106/0001140361-24-026106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036124026106/ef20028923_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-026106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer